Exelixis' future depends on trial outcomes and patent risks. Find out why EXEL stock is a "Sell" despite cabozantinib's strong performance.

Ladenburg, Germany, 13 March 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech Company developing innovative Antibody Drug Conjugates (ADCs), and HealthCare Royalty (HCRx) today ...

Q4 2024 Earnings Call Transcript March 13, 2025 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.28, expectations were $-0.34. Operator: Hello. Thank you for standing by ...

Another mechanistic clue came from a recent immunotherapy time-of-day study in metastatic renal cell carcinoma ... the evidence is less clear for other cancer treatments. In the recent NSCLC ...

BUFFALO, NY - March 21, 2025 – A new editorial was published in Oncotarget, Volume 16, on March 13, 2025, titled “ No disease ...

Haemolytic disease of the fetus and newborn (HDFN) occurs when there is transplacental passage of maternal immunoglobulin G ...

Clear cell renal cell carcinoma (ccRCC) is a heterogeneous disease that is associated with poor prognosis. Recent works have revealed the significant roles of miRNA in ccRCC initiation and progression ...

Detailed price information for Clearside Biomedi (CLSD-Q) from The Globe and Mail including charting and trades.

FDA representatives from both Gastroenterology and Oncology Divisions provided valuable input into the proposed program and the Company believes there is a clear path forward for ... in the US for ...

Urinalysis is a non-invasive test ... information about renal function. First, the gross assessment evaluates the colour of the urine. Healthy urine is usually clear and light yellow, but urine ...